REGENXBIO Inc. (RGNX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
REGENXBIO Inc. (RGNX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
RGNX - REGENXBIO Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$22.50
DETAILS
HIGH:
$45.00
LOW:
$12.00
MEDIAN:
$19.00
CONSENSUS:
$22.50
UPSIDE:
254.33%
Stock News
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., May 18, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: 2026 RBC Capital Markets Global Healthcare Conference Fireside Chat: Wednesday, May 20 at 9:30am ET Location: New York, NY Stifel 2026 Virtual Ophthalmology Forum Fireside Chat: Tuesday, May 26 at 9:30am ET Location: Virtual Live webcasts of select events can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com.
REGENXBIO Inc. (RGNX) Q1 2026 Earnings Call Transcript
REGENXBIO Inc. (RGNX) Q1 2026 Earnings Call Transcript
REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval
REGENXBIO Inc. (NASDAQ:RGNX) on Thursday released topline and interim functional data from the pivotal Phase 1/2/3 AFFINITY DUCHENNE trial evaluating RGX-202, its investigational gene therapy for Duchenne muscular dystrophy.
Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates
Regenxbio (RGNX) came out with a quarterly loss of $1.72 per share versus the Zacks Consensus Estimate of a loss of $1.36. This compares to earnings of $0.12 per share a year ago.
REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights
Company announced positive topline results from pivotal Phase III AFFINITY DUCHENNE ® study of RGX-202 Primary endpoint achieved with high statistical significance Statistically significant correlation between RGX-202 microdystrophin expression and functional improvement (NSAA, n=9), supporting validity of surrogate endpoint Surabgene lomparvovec (sura-vec, ABBV-RGX-314) on track toward key catalysts Sites activated in pivotal Phase IIb/III study for diabetic retinopathy; first patient dosed expected Q2 2026 Subretinal wet AMD topline pivotal data expected in Q4 2026 Clinical hold lifted for RGX-121 Webcast today at 8:00 a.m. ET to discuss RGX-202 topline pivotal data and Q1 2026 earnings ROCKVILLE, Md.
Regenxbio's muscle disorder therapy meets main goal in late-stage study
Regenxbio said on Thursday that its experimental therapy to treat a muscle-wasting disorder met the main goal in a late-stage study.
REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202
Achieved primary endpoint with high statistical significance; 93% of patients achieved microdystrophin expression above 10% (p
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting
ROCKVILLE, Md., May 7, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the 2026 American Society of Gene & Cell Therapy Annual Meeting ("ASGCT 2026") taking place May 11-15, 2026, in Boston, Massachusetts.
REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy
-- Company will also report first quarter 2026 financial results and operational highlights -- ROCKVILLE, Md., May 6, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a webcast on Thursday, May 14, 2026, at 8:00 a.m.
REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX
LOS ANGELES, April 14, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against REGENXBIO Inc. ("Regenxbio" or "the Company") (NASDAQ: RGNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of RGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
RGNX Deadline Today: RGRX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit
NEW YORK, April 14, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the "Class Period"), of the important April 14, 2026 lead plaintiff deadline. So what: If you purchased REGENXBIO securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm
New York, New York--(Newsfile Corp. - April 14, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against REGENXBIO Inc. (NASDAQ: RGNX) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired REGENXBIO securities between February 9, 2022 and January 27, 2026, both dates inclusive (the "Class Period").
RGNX Deadline Today: Rosen Law Firm Urges REGENXBIO, Inc. (NASDAQ: RGNX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”). REGENXBIO is a clinical-stage biotechnology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that REGENXBIO, Inc.
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of the Securities Class Action Lawsuit Deadline on April 14, 2026
NEW YORK--(BUSINESS WIRE)---- $RGNX #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against REGENXBIO Inc. (“REGENXBIO” or the “Company”) (NASDAQ: RGNX) and reminds investors of the April 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has.
Portnoy Law Firm Announces Class Action on Behalf of REGENXBIO, Inc. Investors
LOS ANGELES, April 14, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises REGENXBIO, Inc., (“REGENXBIO” or the "Company") (NASDAQ: RGNX) investors of a class action on behalf of investors that bought securities between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”). REGENXBIO investors have until April 14, 2026 to file a lead plaintiff motion.
RGNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in REGENXBIO Inc. Securities Lawsuit -- The Gross Law Firm
NEW YORK, April 14, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of REGENXBIO Inc. (NASDAQ: RGNX). Shareholders who purchased shares of RGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Faruqi & Faruqi, LLP Highlights Class Action Against REGENXBIO (RGNX) and Upcoming Lead Plaintiff Deadline of April 14, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In REGENXBIO To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in REGENXBIO between February 9, 2022 and January 27, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - April 13, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against REGENXBIO Inc. ("REGENXBIO" or the "Company") (NASDAQ: RGNX) and reminds investors of the April 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
REGENXBIO DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class Action - RGNX
New York, New York--(Newsfile Corp. - April 13, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the "Class Period"), of the important April 14, 2026 lead plaintiff deadline. SO WHAT: If you purchased REGENXBIO securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Levi & Korsinsky, LLP: RGNX Disclosure Timeline Reveals Pattern of Alleged Investor Harm
NEW YORK, April 13, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP encourages investors who suffered losses in REGENXBIO, Inc. (NASDAQ: RGNX) to contact the firm. Those who purchased RGNX securities between February 9, 2022 and January 27, 2026 may be entitled to recover damages.
Price Targets
Regenxbio price target lowered to $16 from $17 at Morgan Stanley
$16.00
(was $6.31)
Morgan Stanley
Regenxbio price target lowered to $12 from $37 at Barclays
$12.00
(was $6.25)
Eliana Merle
·
Barclays
Regenxbio price target lowered to $30 from $32 at H.C. Wainwright
$30.00
(was $10.38)
H.C. Wainwright
Regenxbio Inc. (RGNX) PT Lowered to $17 at Morgan Stanley
$17.00
(was $8.72)
Judah Frommer
·
Morgan Stanley
Regenxbio price target lowered to $32 from $34 at H.C. Wainwright
$32.00
(was $8.91)
H.C. Wainwright
Regenxbio price target lowered to $27 from $39 at Baird
$27.00
(was $8.92)
Brian Skorney
·
Robert W. Baird
Regenxbio price target lowered to $18 from $25 at Morgan Stanley
$18.00
(was $8.96)
UBS
Regenxbio price target lowered to $12 from $14 at Goldman Sachs
$12.00
(was $10.31)
Goldman Sachs
H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX)
$34.00
(was $11.52)
Yi Chen
·
H.C. Wainwright
Regenxbio assumed with an Overweight at Barclays
$37.00
(was $13.41)
Barclays
Regenxbio price target raised to $45 from $40 at Stifel
$45.00
(was $13.51)
Stifel Nicolaus
Regenxbio Inc. (RGNX) PT Raised to $20 at Leerink Partners
$20.00
(was $13.88)
Mani Foroohar
·
Leerink Partners
Sarepta news opens door for Regenxbio over risk/benefit profile, says Leerink
$24.00
(was $7.80)
Leerink Partners
Regenxbio price target lowered to $30 from $35 at RBC Capital
$30.00
(was $8.36)
Luca Issi
·
RBC Capital
Morgan Stanley Assumes Regenxbio Inc. (RGNX) at Overweight
$22.00
(was $11.14)
Judah Frommer
·
Morgan Stanley
Regenxbio reinstated with an Outperform at Raymond James
$18.00
(was $9.19)
Danielle Brill
·
Raymond James
H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX)
$39.00
(was $11.38)
Yi Chen
·
H.C. Wainwright
Stifel Reiterates Buy Rating on Regenxbio Inc. (RGNX)
$40.00
(was $12.79)
Annabel Samimy
·
Stifel Nicolaus
Goldman Sachs Starts Regenxbio Inc. (RGNX) at Buy
$38.00
(was $13.76)
Paul Choi
·
Goldman Sachs
Regenxbio price target raised to $38 from $36 at H.C. Wainwright
$38.00
(was $15.80)
Yi Chen
·
H.C. Wainwright